SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as the community discusses the stock's volatility and potential for a short squeeze. Recent news of a contract win is fueling optimism, though a proposed increase in authorized shares has sparked concerns about dilution. Bullish investors are focused on the company's long-term prospects in the drone and counter-UAS technology sectors.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Olema Pharmaceuticals is trending following positive data from Roche on a similar breast cancer drug, sparking significant intraday volatility and a surge in price. The community is actively debating whether this jump is justified, discussing potential short squeezes, imminent offerings, and the overall valuation of OLMA in light of the news. Some traders are wary of a potential pullback, while others see further upside based on pipeline potential and analyst upgrades.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending due to its GPU-accelerated quantum algorithm simulation and compatibility with NVIDIA's CUDA-Q, sparking discussions about accelerated quantum computing. Investors are speculating on potential partnerships, future growth, and the company's positioning within the quantum computing sector. Community members are also discussing the potential for a short squeeze.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending as community members speculate about a potential acquisition by Nestle, fueled by rumors and recent activity, including workforce reductions.  The discussion revolves around a possible buyout price and what a deal would mean for shareholders.  Some traders are pointing to technical indicators and options activity, while others express frustration with the company's long-term performance and management.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as retail investors discuss the stock holding its 200-day moving average and anticipate a breakout, with some pointing to a potential 'W' pattern forming. Community members are actively trading the swings and expressing excitement around potential catalysts, including a possible World Cup contract and Nvidia's earnings. Bullish sentiment seems to be increasing as traders hope for a power hour surge and speculate on news of new contracts soon.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending amid anticipation for its earnings report, with the community debating whether AI demand justifies current valuations. Discussions include potential sales of advanced AI chips to Saudi Arabia and comparisons to past market bubbles, while some traders are closely watching for a potential breakout.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending as anticipation builds for presentations at the upcoming AASLD Liver Meeting, with the community focused on new biomarker data and potential partnerships. Discussion is centered on Belapectin's potential synergy with GLP-1 drugs and speculation about a possible short squeeze, given the high short interest. Investors are closely watching for any indications of a potential buyout before the year's end.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target (TGT) is trending as investors anticipate upcoming earnings and assess its potential as a value play, considering its lower valuation compared to industry peers. Community members are weighing the possibility of a post-earnings move to $100+, while some caution against potential economic headwinds impacting retail and consumer spending during the holiday season.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

ARWR is trending due to the FDA approval of REDEMPLO for familial chylomicronemia syndrome, marking its first drug approval. The community is excited about the company transitioning to a commercial stage and its robust pipeline, with some drawing comparisons to ALNY's market capitalization. Discussions also revolve around the drug's advantages over competitors and potential partnerships.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors discuss the company's potential in the rapidly growing GLP-1 market, particularly its drug targeting nausea and vomiting related to weight loss medications. Community members are debating potential buyout scenarios and fair valuation, given the company's recent news and cash position. Bullish sentiment revolves around high relative strength and expectations for financial companies to issue positive price target reports.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NOVONIX (NASDAQ:NVX) Trading Up 4.5% - What's Next?

NOVONIX (NASDAQ:NVX) Trading Up 4.5% - Still a Buy...

Asian battery stocks soar as US plans tariffs on Chinese graphite

Investing.com-- Asian battery and graphite-related stocks soared on Friday after the U.S. Commerce Department announced preliminary anti-dumping duties of 93.5% on anode-grade graphite imports from China, a key feedstock for electric vehicle batteries.

NOVONIX Charges Ahead in Battery Sector

NOVONIX Ltd (AU:NVX) has released an update. NOVONIX Ltd has made significant strides in the battery materials sector, securing a US$103 million ta...

12 acciones de tecnolog as de la informaci n en movimiento durante la preapertura del 04/04/2024

Acciones al alza
NOVONIX (NASDAQ:NVX) ganaron un 19,83% para establecerse en los 2,96 d lares durante la sesi n del pre-market del jueves.
Peraso (NASDAQ:PRSO) ganaron un 15,10% para establecerse en...

NOVONIX Limited and Lithium Energy Limited to Combine Natural Graphite Interests with Intention to Take Combined Business Public

NOVONIX Limited ( NOVONIX ) and Lithium Energy Limited ( LEL ) to contribute their natural graphite exploration interests into a new company, Axon Graphite Limited ( Axon )Shares of Axon to be...

Novonix selected by U.S. DOE to receive $103M in tax credits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

U.S. Government Selects NOVONIX to Receive US$103 Million in Qualifying Advanced Energy Project Tax Credits

BRISBANE, Australia, April 01, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) ( NOVONIX or the Company ), a leading battery materials and technology company, today announced...

NOVONIX (NASDAQ:NVX) and NeoVolta (NASDAQ:NEOV) Critical Analysis

NOVONIX (NASDAQ:NVX - Get Free Report) and NeoVolta (NASDAQ:NEOV - Get Free Report) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two...

Reviewing NOVONIX (NASDAQ:NVX) and NeoVolta (NASDAQ:NEOV)

NOVONIX (NASDAQ:NVX  Get Free Report) and NeoVolta (NASDAQ:NEOV  Get Free Report) are both small-cap computer and technology companies, but which is the better investment? We will...

NOVONIX Releases Inaugural Sustainability Report

BRISBANE, Australia, March 08, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) ( NOVONIX or the Company ), a leading battery materials and technology company, today announced...

NOVONIX Ltd. is an integrated developer and supplier of materials, equipment and services for the global lithium-ion battery industry with operations in the U.S. and Canada. It produces synthetic graphite anode materials used in the making of lithium-ion batteries that power electric vehicles, personal electronics, medical devices and energy storage units. The firm operates through the following segments: Battery Materials, Battery Technology, and Graphite Exploration. NOVONIX was founded by Gregory Alexander John Baynton in April 2012 and is headquartered in Brisbane, Australia.

Current Price	$1.18
Prev Close	$1.17
Open	$1.17
Dividend Yield	0.00%
50-Day Moving Average	$1.58
Beta	1.50
Avg. Volume	7.6M
PE Ratio	-2.37

52-Week High	$3.86
52-Week Low	$0.81
Market Capitalization	$245.71M
EPS (Annual)	-$0.601
Price to Book	1.34
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

NVX
Novonix Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest NVX News

NVXNovonix Limited - ADR